SuperworthNational Vision revenue EYE
Sales by quarter and over the last twelve months, from 2016.
- Last 12 months, to Jul 4, 2026
- $2B
- Latest quarter, Q2 FY26
- $498.8M
- +3% on a year earlier
- Fiscal year 2025
- $2B
- +9% on the year before
National Vision's revenue was $2B over the twelve months to Jul 4, 2026, up 8% on a year earlier.
In its latest quarter, Q2 FY26, it was $498.8M, up 3% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 3% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $2B | +9% |
| FY2024 | $1.8B | +4% |
| FY2023 | $1.8B | −12% |
| FY2022 | $2B | −4% |
| FY2021 | $2.1B | +21% |
| FY2020 | $1.7B | −1% |
| FY2019 | $1.7B | +12% |
| FY2018 | $1.5B | +12% |
| FY2017 | $1.4B | +15% |
| FY2016 | $1.2B | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $498.8M | +3% | $2B | |
| Q1 FY26 | $543.9M | +7% | $2B | |
| Q4 FY25 | $503.4M | +15% | $2B | |
| Q3 FY25 | $487.3M | +8% | $1.9B | |
| Q2 FY25 | $486.4M | +8% | $1.9B | |
| Q1 FY25 | $510.3M | +6% | $1.9B | |
| Q4 FY24 | $437.3M | +4% | $1.8B | |
| Q3 FY24 | $451.5M | +3% | $1.8B | |
| Q2 FY24 | $451.7M | +5% | $1.8B | |
| Q1 FY24 | $482.8M | +4% | $1.8B | |
| Q4 FY23 | $421M | −10% | $1.8B | |
| Q3 FY23 | $438.8M | −12% | $1.8B |
Against its peers
Companies in Medical - Instruments & Supplies nearest National Vision's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| EYENational Vision | $2B | +8% a year |
| CDRECadre | $685.6M | +20% a year |
| BVSBioventus | $581.8M | +3% a year |
| STAAStaar Surgical | $339.6M | +51% a year |
| LMATLemaitre Vascular | $262.4M | +12% a year |
| IRMDIradimed | $86.3M | +11% a year |
| INSPInspire Medical Systems | $898.7M | +4% a year |
| UFPTUFP Technologies | $631.6M | +7% a year |
| ATRCAtriCure | $569.6M | +14% a year |
| MOVMovado | $689.9M | +5% a year |
| WRBYWarby Parker | $911.6M | +11% a year |
| Peer median | $606.7M |
Where National Vision ranks
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on National Vision
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.